CompanyGraph
At a glance
- Depends onMidstream position: 5 outgoing, 4 incoming connections
- ScaleRevenue is $747,257, lower than 95% of all stocks globally
- FinancialsLow earnings quality
- Interpretations1 currently firing — 1
Sign in to view price data.
Sign inThe reported statements, read against the company's own industry.
Financials view
Market Capitalization
92.09BINR967.19M · vs all stocks (USD)
Revenue (TTM)
71.15MINR747.26K · vs all stocks (USD)
Beta
0.8350xvs all stocks
52-Week Change
13.79%vs all stocks
Market Capitalization
92.09BINR967.19M · vs all stocks (USD)
Enterprise Value
68.55BINR719.96M · vs all stocks (USD)
Forward P/E
16.84xPrice to Book (MRQ)
12.44xEnterprise to Revenue
963.47xEnterprise to EBITDA
-24.09xGross Margin
100.00%Operating Margin
-3435.00%Return on Assets (TTM)
-47.75%Return on Equity (TTM)
-78.80%Revenue (TTM)
71.15MINR747.26K · vs all stocks (USD)
Revenue per Share (TTM)
0.3120INRUpdated Jul 20, 2026Quarterly Revenue Growth
3.60%Gross Profit (TTM)
71.15MINR747.26K · vs all stocks (USD)
EBITDA (TTM)
-2.85BINR-29.88M · vs all stocks (USD)
Net Income (TTM)
-2.76BINR-29.02M · vs all stocks (USD)
Quarterly Earnings Growth (YoY)
3.62%Operating Cash Flow (TTM)
-3.02BINR-31.70M · vs all stocks (USD)
Levered Free Cash Flow (TTM)
-1.98BINR-20.78M · vs all stocks (USD)
5-Year Average Dividend Yield
0.69%vs all stocks
Payout Ratio
0.00%Revenue
71.15MINRFY2026 · Mar 31, 2026Cost of Goods Sold
0.00INRFY2026 · Mar 31, 2026Gross Profit
71.15MINRFY2026 · Mar 31, 2026Operating Income
-2.90BINR-30.47M · vs all stocks (USD)
Pre-tax Income
-2.76BINRFY2026 · Mar 31, 2026Income Tax Expense
0.00INRFY2026 · Mar 31, 2026Net Income
-2.76BINRFY2026 · Mar 31, 2026EBIT
-2.76BINRFY2026 · Mar 31, 2026EBITDA (Income Statement)
-2.71BINRFY2026 · Mar 31, 2026Research & Development
2.48BINRFY2026 · Mar 31, 2026Other Operating Expenses
192.80MINRFY2026 · Mar 31, 2026Non-operating Interest Expense
1.58MINRFY2026 · Mar 31, 2026EPS (Basic)
-12.13INRFY2026 · Mar 31, 2026EPS (Diluted)
-12.13INRFY2026 · Mar 31, 2026Basic Shares Outstanding
227.82MSharesFY2026 · Mar 31, 2026Diluted Shares Outstanding
227.82MSharesFY2026 · Mar 31, 2026Net Income from Continuing Operations
-2.76BINRFY2026 · Mar 31, 2026Preferred Stock Dividends
0.00INRFY2026 · Mar 31, 2026Operating Cash Flow
-2.97BINRFY2026 · Mar 31, 2026Free Cash Flow
-3.02BINRFY2026 · Mar 31, 2026Cash & Cash Equivalents (End of Period)
82.79MINRFY2026 · Mar 31, 2026Starting Profit (CF Statement)
-2.76BINRFY2026 · Mar 31, 2026Stock-based Compensation
17.87MINRFY2026 · Mar 31, 2026Other Non-cash Items
-44.63MINRFY2026 · Mar 31, 2026Change in Accounts Receivable (CF)
-1.72MINRFY2026 · Mar 31, 2026Change in Other Assets/Liabilities
-173.67MINRFY2026 · Mar 31, 2026Capital Expenditures
-50.83MINRFY2026 · Mar 31, 2026Other Investing Activity
-9.62MINRFY2026 · Mar 31, 2026Net Investing Cash Flow
-60.45MINRFY2026 · Mar 31, 2026Net Financing Cash Flow
7.57BINRFY2026 · Mar 31, 2026Shares Outstanding
263.72MSharesUpdated Jul 20, 2026Float Shares
64.19MSharesUpdated Jul 20, 2026% Held by Insiders
66.64%vs all stocks
% Held by Institutions
2.88%vs all stocks
Total Cash (MRQ)
5.18BINR54.42M · vs all stocks (USD)
Total Cash per Share (MRQ)
22.95INRUpdated Jul 20, 2026Total Debt (MRQ)
166.94MINR1.75M · vs all stocks (USD)
Total Debt to Equity (MRQ)
0.0282xCurrent Ratio (MRQ)
17.70xBook Value per Share (MRQ)
26.20INRUpdated Jul 20, 2026Total Assets
6.24BINR65.56M · vs all stocks (USD)
Total Current Assets
5.47BINRFY2026 · Mar 31, 2026Total Liabilities
328.14MINRFY2026 · Mar 31, 2026Total Non-current Assets
775.05MINRFY2026 · Mar 31, 2026Total Non-current Liabilities
19.17MINRFY2026 · Mar 31, 2026Total Current Liabilities
308.97MINRFY2026 · Mar 31, 2026Cash & Cash Equivalents
82.79MINRFY2026 · Mar 31, 2026Other Short-term Investments
5.14BINRFY2026 · Mar 31, 2026Accounts Receivable
15.08MINRFY2026 · Mar 31, 2026Inventory
1.02MINRFY2026 · Mar 31, 2026Accounts Payable
48.13MINRFY2026 · Mar 31, 2026Short-term Debt
166.94MINRFY2026 · Mar 31, 2026Other Current Liabilities
22.26MINRFY2026 · Mar 31, 2026Common Stock (Book)
263.72MINRFY2026 · Mar 31, 2026Total Shareholders' Equity
5.91BINR62.11M · vs all stocks (USD)
52-Week Low
124.11INRUpdated Jul 20, 202652-Week High
371.00INRUpdated Jul 20, 202652-Week Change
13.79%vs all stocks
Beta
0.8350xvs all stocks
50-Day MA
277.20INRUpdated Jul 20, 2026200-Day MA
196.00INRUpdated Jul 20, 2026Avg 10-Day Volume
1.60MSharesUpdated Jul 20, 2026Avg 30-Day Volume
1.96MSharesUpdated Jul 20, 2026Diluted EPS (TTM)
-12.12INRUpdated Jul 20, 20261 interpretation currently present — each is a set of fired observations whose alignment reads as one structural pattern. Click an observation to see the numbers behind it.
Screen for these patternsIs this company growing?
Diagnostic
High R&D Share With Multi-Year Share-Count Growth and Elevated SBC
Heavy R&D and stock pay, with the share count growing across six years.
Reads
An interpretation is present only while every observation it reads stays fired (score ≥ 70). It describes what the aligned readings show — never a verdict, never a prediction.
Shared structure with peers — never a ranking.
Relationships view
Structural observations derived from financial data, industry benchmarks, and supply chain position.
Financial Health
Low earnings qualitySignificant
Earnings Quality Score: -0.62
Supply Chain
Midstream position: 5 outgoing, 4 incoming connectionsNotable
Outgoing: 5.00Incoming: 4.00
Scale
Revenue is $747,257, lower than 95% of all stocks globallySignificant
Revenue (USD): 747,256.941Global P5: 30,274,777.221
Companies that share the same coordination system — how they create, deliver, or capture value.
Seegene, Inc.
Tier 1ProductionApproval-Gated PipelineRule
Chengdu Kanghua Biological Products Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRuleFlow
Kura Oncology Inc.
Tier 1ProductionApproval-Gated PipelineRuleRisk
Bide Pharmatech Co. Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Hunan Er-Kang Pharmaceutical Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Hob Biotech Group Suzhou Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Tianjin Tianyao Pharmaceuticals Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Youcare Pharmaceutical Group Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRuleFlow
Green Cross Corporation
Tier 1ProductionApproval-Gated PipelineRule
Chongqing Pharscin Pharmaceutical Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Companies that share active interpretations — structural patterns currently present in both stocks.
Immunome Inc.
1 interpretationHigh R&D Share With Multi-Year Share-Count Growth and Elevated SBC
Hyliion Holdings Corp.
1 interpretationHigh R&D Share With Multi-Year Share-Count Growth and Elevated SBC
Kopin Corporation
1 interpretationHigh R&D Share With Multi-Year Share-Count Growth and Elevated SBC